MGTX - NASDAQ

MeiraGTx Holdings plc

MeiraGTx Holdings plc

MGTX·NASDAQ

$9.39

+1.6%
HealthcareBiotechnology

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$869.60M
EPS-1.4200
P/E Ratio-6.61
Earnings Date08/06/2026
-46.36M
Operating Cash Flow
-56%
3Y-37.0%
5Y-28.0%
10Y+223.0%
-4.11M
Investing Cash Flow
-117%
3Y-91.0%
5Y-89.0%
10Y+58.0%
12.27M
Financing Cash Flow
-77%
3Y-87.0%
5Y-85.0%
10Y-41.0%
MGTX

MeiraGTx Holdings plc Cash Conversion Engine

MGTX · NASDAQ
Net Income-114.20M
Depreciation & Amortization12.70M
Stock-Based Compensation22.11M
Change in Working Capital28.03M
Others5.01M
Capital Expenditures-3.83M
Free Cash Flow-50.19M

Cash Flow Quality Analysis

FCF Conversion Rate

43.9%

Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.

CapEx Intensity

-8.3%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

+54.1%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

+$28.03M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

MeiraGTx Holdings plc Cash Flow Statement

MGTX • NASDAQ

MeiraGTx Holdings plc Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
OPERATING ACTIVITIES
Net Income
-114.2M
-147.8M
-84M
-129.6M
-79.6M
-58M
-54.7M
-82.9M
-31M
-19.8M
Depreciation & Amortization
12.7M
12.7M
13.7M
8.6M
7.9M
4.2M
2.2M
2.1M
679.2K
243.1K
Change in Deferred Taxes
0.0
0.0
0.0
0.0
0.0
0.0
-3.2M
-474.4K
-1.2M
-261.8K
Stock-Based Compensation
22.1M
25.2M
27.7M
28.6M
20.8M
18.4M
15.9M
17.9M
3M
2.8M
Other Non-Cash Items
5M
-24.2M
-61.8M
9.7M
9.1M
4.1M
2M
8.4M
2M
1.1M
Change in Working Capital
28M
29.6M
-983K
9.6M
31.3M
-32.6M
57.8M
-3.9M
8.5M
1.6M
Cash from Operating Activities
-46.4M
-104.5M
-105.4M
-73.1M
-10.5M
-64M
20M
-58.9M
-18.1M
-14.4M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment
-3.8M
-5M
-20.2M
-45M
-55.2M
-34.9M
-9M
-11.3M
-10.5M
-2.6M
Acquisitions, Net
(0.0)
(0.0)
(0.0)
(0.0)
-6.5M
(0.0)
-389.7K
(0.0)
(0.0)
(0.0)
Other Investing Items
-281K
28.4M
54.2M
0.0
0.0
-2.1M
-389.7K
0.0
0.0
0.0
Cash from Investing Activities
-4.1M
(23.5M)
(34M)
-45M
-61.7M
-37M
-9.4M
-11.3M
-10.5M
-2.6M
FINANCING ACTIVITIES
Net Issuance of Common Stock
15.3M
59.4M
92M
25M
0.0
87.1M
155.2M
69.8M
0.0
0.0
Net Issuance of Debt
-29K
0.0
0.0
75M
-1K
-23K
-24.9K
-30.9K
2.5M
-5.5K
Other Financing Items
-3M
-4.9M
-7.9M
-4.8M
1.7M
-4.3M
-6.9M
130.1M
16.9M
0.0
Cash from Financing Activities
12.3M
54.5M
84M
95.2M
1.7M
82.7M
148.2M
130M
19.3M
20.8M
CASH FLOW SUMMARY
Effect of Foreign Exchange Rates
719K
1.5M
2.4M
674K
-1.3M
422K
243.5K
-362.5K
1.4K
-421.2K
Net Change in Cash
-37.5M
-25M
15.1M
-22.2M
-71.8M
-17.8M
159.2M
59.5M
-9.2M
3.4M
Cash at Beginning of Period
105.7M
130.6M
115.5M
137.7M
209.5M
227.4M
68.2M
8.7M
17.9M
14.5M
Cash at End of Period
68.2M
105.7M
130.6M
115.5M
137.7M
209.5M
227.4M
68.2M
8.7M
17.9M
Free Cash Flow
-50.2M
-109.5M
-125.5M
-118.1M
-65.7M
-101M
11.1M
-70.1M
-28.6M
-17M

SEC Filings

MGTX - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
10-Q

10-Q 2026 Q1

Q1

May 14, 2026
March 31, 2026
2026
View Filing
8-K

8-K 2026

N/A

May 14, 2026
May 14, 2026
2026
View Filing
DEF 14A

DEF 14A 2026

N/A

April 30, 2026
June 11, 2026
2026
View Filing
8-K

8-K 2026

N/A

April 24, 2026
April 20, 2026
2026
View Filing
8-K

8-K 2026

N/A

April 16, 2026
April 16, 2026
2026
View Filing
8-K

8-K 2026

N/A

April 16, 2026
April 15, 2026
2026
View Filing
8-K

8-K 2026

N/A

April 16, 2026
April 16, 2026
2026
View Filing
10-K

10-K 2025 FY

FY

March 30, 2026
December 31, 2025
2025
View Filing
8-K

8-K 2026

N/A

March 26, 2026
March 25, 2026
2026
View Filing
8-K

8-K 2025

N/A

January 02, 2026
December 31, 2025
2025
View Filing
Showing 1 to 10 of 131 filings

Related Guides

Blog Categories

Continue your MGTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.